SLC5A2 and diabetes mellitus: The present study demonstrated for the first time that the combination of SGLT2 inhibitor and DPP-4 inhibitor can synergistically ameliorate NASH with stronger anti-fibrotic effects compared with each drug alone in a new model of NASH and diabetes, because we found that the extent of liver fibrosis evaluated by Sirius red and alpha-SMA staining was significantly smaller in the combination of empagliflozin and linagliptin group than in the empagliflozin group or the linagliptin group.